Care Continuation Beyond the First 90 Days

The first 90 days are a starting scope

A first-90-days program gives a clinic a defined period for onboarding, planned support, clarification of obstacles and preparation for a care review. It does not imply that all patients settle into a routine at the same time or that support becomes unnecessary on day 91.

Use actual care milestones rather than assuming a universal treatment calendar. A delayed start, clinic-directed pause or changed plan may alter what is relevant. Keep the program’s commercial period separate from the patient’s treatment timeline so a reporting deadline does not become a clinical deadline.

Carry forward the information that matters

At the review, bring together the patient’s stated concerns, dated care events, assistance already provided and unresolved questions. Do not require the patient to repeat an access problem that was documented earlier, or let a new automated sequence ignore a pending clinical conversation.

The clinic decides the next care plan. The engagement program can help organize preparation and administrative follow-through, including a planned pause or transfer. A completed review, an agreed next step and continued treatment are distinct outcomes. Record each rather than treating the end of the first program period as proof of successful long-term retention.

Adapt the support without assuming why behavior changed

A patient who replies less often may prefer less contact, have a technical issue or no longer need the same support. Another may have an unresolved concern. A change in response pattern should prompt a proportionate check using available evidence, not an automatic conclusion about motivation.

Review communication preferences, current care needs and whether existing messages remain useful. Avoid repeating first-week content to someone who needs review preparation, and avoid sending continuation prompts while clinical questions remain unresolved. The next program phase should follow the updated care plan and what the patient has actually told the team.

Measure longer-term outcomes with enough follow-up

A 90-day commercial pilot may end before later-enrolled patients have completed 90 days of treatment. Define the enrollment cutoff, observation window and how pending outcomes will be reported. Longer-term continuation requires longer-term evidence; it cannot be inferred from an early reply rate.

If the clinic extends the evaluation, retain consistent definitions and document changes to the program. Report care outcomes, patient experience, staff effort and collected contribution over the observed horizon. Separate appropriate exits from unexplained loss to follow-up, and avoid extrapolating a short-term difference into a multi-year value claim.

Practical review checklist

• The first 90 days is a scope, not a universal cliff. Synarmic’s initial offer focuses on a defined early treatment journey. That does not mean every patient encounters the same difficulty in the same week, or that most discontinuation necessarily occurs within this window.
• Review before extending. At the review point, consider the patient’s concerns, completed care, remaining support needs and current clinical plan. Ongoing support should reflect those findings rather than automatically repeating an introductory sequence.
• Separate future scope from current capability. Maintenance and later-stage journeys are possible extensions to evaluate after the initial program. They require their own approved content, data requirements and outcome definitions. Success in an early cohort would not by itself establish long-term clinical benefit.